J07BC20 - Combinations |
Propably not porphyrinogenic |
PNP |
Rationale
Based on the pharmacokinetics of the hepatitis combination vaccine, there are no conceivable porphyrinogenic effects.
Chemical description
Inactivated hepatitis A virus and hepatitis B virus surface antigen.
Therapeutic characteristics
The hepatitis combination vaccine is indicated for use in non-immune adults and children from the age of 1 year and above who are at risk of both hepatitis A and hepatitis B infection. It is administered by intramuscular injections according to a three or four dose schedule.
Metabolism and pharmakokinetics
The hepatitis vaccine is not metabolized by the cytochrome P450 system.
IPNet drug reports
Uneventful use reported in 3 patients with acute porphyria.
References
- Government bodies
- Norwegian Institute of Public Health. Vaksinasjonsveilederen. www.fhi.no (updated 13.10.2015). #1857
- Summary of Product Characteristics
- The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Twinrix. (Last edition: January 2015). #1877
Similar drugs
© NAPOS 2024